Journal article
Economic issues in glycoprotein IIb/IIIa receptor therapy
Abstract
Efficacy, safety, and cost will determine the use of glycoprotein IIb/IIIa therapy in patients with acute coronary syndromes or those patients undergoing percutaneous coronary intervention (PCI). Prospective randomized studies with abciximab, eptifibatide, and tirofiban have demonstrated the superior efficacy and relative safety of IIb/IIIa therapy in these 2 broad patient groups. In medical practice, we by necessity make decisions to …
Authors
Hillegass WB; Newman AR; Raco DL
Journal
American Heart Journal, Vol. 138, No. 1, pp. s24–s32
Publisher
Elsevier
Publication Date
July 1999
DOI
10.1053/hj.1999.v138.99079
ISSN
0002-8703